Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya.
暂无分享,去创建一个
D. Kimanga | L. Nganga | S. Pals | R. Ondondo | E. Ngugi | Nancy Bowen | A. Aoko | Kenneth Masamaro | F. Basiye | Salome Okutoyi | P. Musingila | B. Mambo | Helen M Chun | R. Joseph | Lazarus O. Momanyi | Maureen Kimani | Elizabeth Katiku | Timothy N Ngugi | Valeria Makory | Rose Ayugi
[1] R. Madrid,et al. Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status , 2021, Virulence.
[2] T. Klimkait,et al. Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. , 2021, The Journal of antimicrobial chemotherapy.
[3] Hansjakob Furrer,et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study , 2019, The Lancet.
[4] A. Wensing,et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study , 2018, The lancet. HIV.
[5] A. Esber,et al. Persistent low level viremia predicts subsequent virologic failure. Is it time to change the 3rd 90? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] D. Cooper,et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. , 2018, The lancet. HIV.
[7] Diederick E Grobbee,et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. , 2017, The Lancet. Infectious diseases.
[8] M. Wainberg,et al. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. , 2017, Virus research.
[9] M. Gisslén,et al. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment , 2017, PloS one.
[10] Daniel I. S. Rosenbloom,et al. Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics , 2017, The Journal of experimental medicine.
[11] S. Hughes,et al. Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir , 2017, PLoS pathogens.
[12] J. Gallant,et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.
[13] Pietro Vernazza,et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. , 2016, JAMA.
[14] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[15] R. Salamon,et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.
[16] Art-Cc. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients , 2015 .
[17] D. Bangsberg,et al. Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia , 2015, Open forum infectious diseases.
[18] P. Harrigan,et al. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure , 2014, AIDS.
[19] H. Trottier,et al. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] C. Delaugerre,et al. Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients , 2012, PloS one.
[21] G. Palù,et al. Baseline Cellular HIV DNA Load Predicts HIV DNA Decline and Residual HIV Plasma Levels during Effective Antiretroviral Therapy , 2011, Journal of Clinical Microbiology.
[22] R. Haubrich,et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. , 2011, The Journal of infectious diseases.
[23] R. Kaul,et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication , 2010, AIDS.
[24] H. Ullum,et al. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.